LV11823B - Establishment of tonic ovarian estrogen secretion for extended therapeutic regiments - Google Patents

Establishment of tonic ovarian estrogen secretion for extended therapeutic regiments Download PDF

Info

Publication number: LV11823B
Authority: LV; Latvia
Prior art keywords: preparation; estrogen; gnrh antagonist; gnrh; proliferation
Prior art date: 1994-07-22

Application number

LVP-97-30A

Other languages

English (en)

Latvian (lv)

Other versions

LV11823A (lv

Inventor

Gary D. Hodgen

Audrey Philips

Original Assignee

The Medical College Of Hampton Roads

Ortho Pharmaceutical Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-22

Filing date

1997-02-26

Publication date

1998-03-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV11823(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-06 Priority claimed from US08/467,860 external-priority patent/US5658884A/en

1997-02-26 Application filed by The Medical College Of Hampton Roads, Ortho Pharmaceutical Corporation filed Critical The Medical College Of Hampton Roads

1997-08-20 Publication of LV11823A publication Critical patent/LV11823A/xx

1998-03-20 Publication of LV11823B publication Critical patent/LV11823B/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

LVP-97-30A 1994-07-22 1997-02-26 Establishment of tonic ovarian estrogen secretion for extended therapeutic regiments LV11823B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US27959394A	1994-07-22	1994-07-22
US08/467,860 US5658884A (en)	1994-07-22	1995-06-06	Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en)	1994-07-22	1995-07-18	Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number	Publication Date
LV11823A LV11823A (lv)	1997-08-20
LV11823B true LV11823B (en)	1998-03-20

Family

ID=26959766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-97-30A LV11823B (en)	1994-07-22	1997-02-26	Establishment of tonic ovarian estrogen secretion for extended therapeutic regiments

Country Status (29)

Country	Link
EP (1)	EP0769956B1 (de)
JP (1)	JP3138477B2 (de)
CN (1)	CN1137722C (de)
AP (1)	AP775A (de)
AT (1)	ATE190494T1 (de)
AU (1)	AU691952B2 (de)
BG (1)	BG63363B1 (de)
BR (1)	BR9508718A (de)
CA (1)	CA2195745C (de)
CY (1)	CY2228B1 (de)
CZ (1)	CZ291803B6 (de)
DE (1)	DE69515666T2 (de)
DK (1)	DK0769956T3 (de)
EE (1)	EE03515B1 (de)
ES (1)	ES2145286T3 (de)
FI (1)	FI970244L (de)
GR (1)	GR3033590T3 (de)
HU (1)	HU218910B (de)
IL (1)	IL114655A (de)
IS (1)	IS4413A (de)
LV (1)	LV11823B (de)
MX (1)	MX9700574A (de)
NO (1)	NO970257D0 (de)
NZ (1)	NZ290554A (de)
OA (1)	OA10730A (de)
PT (1)	PT769956E (de)
RU (1)	RU2181598C2 (de)
SK (1)	SK282118B6 (de)
WO (1)	WO1996003138A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8173592B1 (en)	1999-03-31	2012-05-08	Zentaris Ivf Gmbh	Method for a programmed controlled ovarian stimulation protocol
PL201898B1 (pl) *	1999-09-23	2009-05-29	Zentaris Gmbh	Zastosowanie antagonisty LH-RH w leczeniu endometriozy
DE10137174A1 (de) *	2001-07-31	2003-02-13	Zentaris Ag	Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) *	2006-06-16	2006-09-20	Ardana Bioscience Ltd	Agents, methods and uses
EP2095818A1 (de)	2008-02-29	2009-09-02	AEterna Zentaris GmbH	Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
EP2307040B1 (de) *	2008-05-29	2015-09-09	Isr Immune System Regulation Ab	Gnrh und sexhormone zur behandlung von viruserkrankungen, insbesondere hiv/aids
AU2016264034B2 (en) *	2015-05-18	2020-03-05	KaNDy Therapeutics Limited	Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EA202092131A1 (ru)	2018-03-14	2020-11-27	Кэнди Терапьютикс Лимитед	Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP3560555A1 (de)	2018-04-26	2019-10-30	LifeArc	Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten
US12533358B1 (en)	2025-05-14	2026-01-27	Bayer Consumer Care Ag	Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5171835A (en) *	1988-10-21	1992-12-15	The Administrators Of The Tulane Educational Fund	LHRH antagonists
US5169932A (en) *	1989-10-30	1992-12-08	The Salk Institute For Biological Studies	Gnrh analogs
US5211952A (en) *	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
ZA924811B (en) *	1991-06-28	1993-12-29	Endorecherche Inc	Controlled release systems and low dose androgens
US5681817A (en) *	1994-02-04	1997-10-28	The Medical College Of Hampton Roads	Treatment of ovarian estrogen dependent conditions
US5407955A (en) *	1994-02-18	1995-04-18	Eli Lilly And Company	Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

1995
- 1995-07-18 WO PCT/US1995/008996 patent/WO1996003138A1/en not_active Ceased
- 1995-07-18 DE DE69515666T patent/DE69515666T2/de not_active Revoked
- 1995-07-18 AU AU31320/95A patent/AU691952B2/en not_active Expired
- 1995-07-18 AP APAP/P/1997/000913A patent/AP775A/en active
- 1995-07-18 HU HU9700046A patent/HU218910B/hu not_active IP Right Cessation
- 1995-07-18 SK SK70-97A patent/SK282118B6/sk not_active IP Right Cessation
- 1995-07-18 PT PT95927228T patent/PT769956E/pt unknown
- 1995-07-18 BR BR9508718A patent/BR9508718A/pt not_active Application Discontinuation
- 1995-07-18 FI FI970244A patent/FI970244L/fi not_active Application Discontinuation
- 1995-07-18 DK DK95927228T patent/DK0769956T3/da active
- 1995-07-18 IL IL11465595A patent/IL114655A/xx not_active IP Right Cessation
- 1995-07-18 EP EP95927228A patent/EP0769956B1/de not_active Revoked
- 1995-07-18 AT AT95927228T patent/ATE190494T1/de not_active IP Right Cessation
- 1995-07-18 CA CA002195745A patent/CA2195745C/en not_active Expired - Lifetime
- 1995-07-18 CN CNB951951696A patent/CN1137722C/zh not_active Expired - Fee Related
- 1995-07-18 ES ES95927228T patent/ES2145286T3/es not_active Expired - Lifetime
- 1995-07-18 EE EE9700208A patent/EE03515B1/xx not_active IP Right Cessation
- 1995-07-18 JP JP08505816A patent/JP3138477B2/ja not_active Expired - Lifetime
- 1995-07-18 MX MX9700574A patent/MX9700574A/es unknown
- 1995-07-18 RU RU97102759/14A patent/RU2181598C2/ru not_active IP Right Cessation
- 1995-07-18 NZ NZ290554A patent/NZ290554A/xx not_active IP Right Cessation
- 1995-07-18 CZ CZ1997150A patent/CZ291803B6/cs not_active IP Right Cessation
1997
- 1997-01-13 OA OA60952A patent/OA10730A/en unknown
- 1997-01-14 IS IS4413A patent/IS4413A/is unknown
- 1997-01-21 BG BG101158A patent/BG63363B1/bg unknown
- 1997-01-21 NO NO970257A patent/NO970257D0/no not_active Application Discontinuation
- 1997-02-26 LV LVP-97-30A patent/LV11823B/en unknown
2000
- 2000-05-31 GR GR20000401285T patent/GR3033590T3/el not_active IP Right Cessation
2001
- 2001-07-26 CY CY0100017A patent/CY2228B1/xx unknown

Also Published As

Publication number	Publication date
CY2228B1 (en)	2003-04-18
IL114655A0 (en)	1995-11-27
FI970244A0 (fi)	1997-01-21
JP3138477B2 (ja)	2001-02-26
WO1996003138A1 (en)	1996-02-08
NZ290554A (en)	2000-08-25
PT769956E (pt)	2000-07-31
BG101158A (bg)	1997-09-30
SK7097A3 (en)	1997-11-05
EP0769956A4 (de)	1999-03-10
GR3033590T3 (en)	2000-09-29
AP775A (en)	1999-10-28
JPH10503203A (ja)	1998-03-24
FI970244A7 (fi)	1997-01-21
AU691952B2 (en)	1998-05-28
DE69515666T2 (de)	2000-07-06
CN1200674A (zh)	1998-12-02
BR9508718A (pt)	1997-12-30
ES2145286T3 (es)	2000-07-01
NO970257L (no)	1997-01-21
MX9700574A (es)	1997-12-31
OA10730A (en)	2001-06-07
ATE190494T1 (de)	2000-04-15
SK282118B6 (sk)	2001-11-06
FI970244L (fi)	1997-01-21
NO970257D0 (no)	1997-01-21
CN1137722C (zh)	2004-02-11
LV11823A (lv)	1997-08-20
HUT77127A (hu)	1998-03-02
AU3132095A (en)	1996-02-22
CA2195745C (en)	2005-03-29
CZ15097A3 (en)	1997-11-12
IS4413A (is)	1997-01-14
DE69515666D1 (de)	2000-04-20
CZ291803B6 (cs)	2003-06-18
IL114655A (en)	2005-08-31
HU218910B (hu)	2000-12-28
EE9700208A (et)	1998-02-16
EP0769956B1 (de)	2000-03-15
BG63363B1 (bg)	2001-11-30
HU9700046D0 (en)	1997-02-28
EP0769956A1 (de)	1997-05-02
CA2195745A1 (en)	1996-02-08
AP9700913A0 (en)	1997-01-31
EE03515B1 (et)	2001-10-15
DK0769956T3 (da)	2000-06-05
RU2181598C2 (ru)	2002-04-27

Publication	Publication Date	Title
EP0785792B1 (de)	1999-05-06	Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
EP0686037B1 (de)	2001-06-20	Hormon-ersatztherapie
Maheux et al.	1987	Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas
CA2195745C (en)	2005-03-29	Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Reichel et al.	1992	Goserelin (Zoladex) depot in the treatment of endometriosis
Bygdeman et al.	1999	Contraceptive use of antiprogestin
US5658884A (en)	1997-08-19	Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Gudmundsson et al.	1984	Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH
Mettler et al.	1991	Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosiss
Pasquale	1984	Rationale for a triphasic oral contraceptive
US5116818A (en)	1992-05-26	Method and kit for contraception with GnRH-antagonist
Lipitz et al.	1989	Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols
Reid et al.	1987	LHRH agonists and antagonists: therapeutic possibilities for premenstrual syndrome
Lemay et al.	1990	Comparison of Buserelin to Danazol Therapy in Endometriosis